Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose st
Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose st
Yuhao Wang, Meixia Chen, Jie Hou, Hanmo Liu et al.
Citations
5 citations
Journal
British Journal of Clinical Pharmacology
Topics
Cystic Fibrosis Research Advances
Field-Weighted Citation Impact (FWCI)
7.59
article
Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose st
Yuhao Wang, Meixia Chen, Jie Hou, Hanmo Liu, Nan Wu, Lu Wang, Chao Yu, Mengyue Hu
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
British Journal of Clinical PharmacologyVol. 91(8)
Institutions
China National Pharmaceutical Group Corporation (China) (CN)